High-dose methylprednisolone taper,
does it really help with Recovery of unilateral vestibular function on caloric testing at 12 months after acute vestibular neuritis?
research showsThe grade is C with 50 points. A German two-center 2-by-2 factorial trial randomized 141 patients but analyzed only 114 who completed 12 months. Improvement in vestibular paresis was 39.6±28.1 points with placebo, 62.4±16.9 with methylprednisolone, 36.0±26.7 with valacyclovir, and 59.2±24.1 with both; the steroid main effect had P<.001. The primary endpoint was a caloric-test value rather than dizziness or quality of life, and 27 randomized patients (19.1%) were excluded.
ads claimThe evidence concerns treatment started within three days using 100 mg initially and tapering over 22 days, with improved testing at 12 months. It does not directly show faster dizziness relief or better quality of life.
Useful facts when choosing a product
- This 2004 report predates modern trial registration, so no registration number exists.
- Methylprednisolone started at 100 mg and tapered over 22 days.
- The 12-month primary analysis used 114 completers rather than all 141 randomized patients.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.tapering-course-of-high-dose-methylprednisolone.UNK.recovery-of-unilateral-vestibular-function-on-caloric-testing-at-after-acute-vestibular-neuritis.assess.MULTIUnknown > tapering course of high-dose methylprednisolone > Unknown > Recovery of unilateral vestibular function on caloric testing at after acute vestibular neuritis > Association or change assessment > Multiple: primary unresolved
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
From 1998 to 2002, 141 patients with acute vestibular neuritis were assigned by computer-generated block randomization to placebo, 38; methylprednisolone, 35; valacyclovir, 33; or both, 35. Twelve-month completers numbered 30, 29, 27, and 28, respectively, totaling 114. The paper states, 'Patients who did not return for the 12-month follow-up examination were excluded from the final analysis.' This was complete-case rather than intention-to-treat analysis, excluding 19.1% of randomized patients. Small enrollment, substantial attrition, and complete-case analysis were counted as avoidable limitations. The article contains no cash-funding section. Hoechst Pharma Germany supplied study drugs and placebo but had no role in design, collection, analysis, manuscript preparation, or publication. Absence of a funding section was not restated as no funding or public funding. Verdict 695 is D with 28 points for betahistine in Ménière's disease; verdict 1692 is B with 76 points for the Epley manoeuvre in posterior-canal BPPV; and verdict 1763 is B with 68 points for vestibular rehabilitation in chronic dizziness. These diseases and interventions differ from acute vestibular neuritis.
Why this is classified as C (50)
A large laboratory effect was found, but a surrogate primary endpoint, one small trial, 19.1% attrition with complete-case analysis, and an unreported cash-funding source give C with 50 points.
Counterpoint. C does not mean the test effect was small. It describes the absence of patient-centered symptoms and substantial analysis loss.
Rejudgment record. Cross-check applied — A large effect on a caloric-test surrogate was found, but this was one small trial whose complete-case analysis excluded 27 of 141 randomized patients, 19.1%
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I1 | Mixed funding sources |
| Effect size | E+ | Meets the clinically important threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Vestibular recovery on caloric testing at 12 months | C | The laboratory effect was large, but analysis used 114 completers. |
| Improved dizziness symptoms or quality of life | ? | The trial did not measure these patient-centered outcomes. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Strupp M et al. 2004 | Double-blind placebo-controlled 2-by-2 factorial randomized trial at two German centers | 141 randomized; 114 completers in the 12-month analysis | No cash-funding section; Hoechst Pharma Germany supplied study drugs and placebo without research involvement | Improvement in unilateral vestibular paresis on caloric testing at 12 months | Improvement 39.6±28.1, 62.4±16.9, 36.0±26.7, and 59.2±24.1 points; methylprednisolone P<.001, valacyclovir P=.43, interaction P=.92 | Single small complete-case laboratory-outcome trial |
Receipt — 4 References
All 4 cited sources were verified for existence at the original page (as of 2026-08-18).
Final verification and publication gate: Codex · Evidence date: 2026-08-18 · Corrections: none
Cite this verdict
[Chamgap] High-dose methylprednisolone taper x caloric-test recovery after acute vestibular neuritis — Evidence Grade C·50. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/general/high-dose-methylprednisolone-acute-vestibular-neuritis-caloric-recovery/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.